Use of faricimab in neovascular age-related macular degeneration and diabetic macular edema in Russia. Results of the FARWATER retrospective study
Faricimab demonstrated high clinical effectiveness in real-world settings in patients with nAMD and DME, with the potential to reduce the treatment burden for patients and the healthcare system.
Authors
- E.D. Bosov
- M.V. Gordeeva
- E.V. Bobykin
- E.V. Karlova
- N. V. Neroeva
- R. R. Faizrakhmanov
- A.A. Plyukhova
- A.A. Nikiforova
- A.Zh. Fursova
Institutions
- Novosibirsk State Medical University (RU)
- Ural State Medical University (RU)
- Helmholtz Moscow Research Institute of Eye Diseases (RU)
- National Medical and Surgical Center named after N.I. Pirogov (RU)
- Ziemer Ophthalmic Systems (Switzerland) (CH)
- Federal State Scientific Institution Research Institute of Eye Diseases (RU)
- Ophthalmology Clinic (DE)
- Samara Regional Clinical Hospital named after V.D. Seredavina (RU)
Publication Details
- Journal
- Russian Annals of Ophthalmology
- Published
- 2025-12-23
- DOI
- https://doi.org/10.17116/oftalma202514106182
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00